Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Qingqing Cai, MD. PhD.
CONTACT
Yi Xia, MD. PhD.
CONTACT
Lead
Sun Yat-sen University
With
The purpose of this phase II clinical trial is to evaluate the efficacy and safety of orelabrutinib in combination with R-CHOP for untreated CD5-positive DLBCL patients. The induction phase consisted of 6 cycles of orelabrutinib in combination with R-CHOP (orelabrutinib added from the second cycle), followed by 2 cycles of rituximab + orelabrutinib, for a total of 8 treatment cycles. After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with orelabrutinib will be conducted. The primary endpoint is the 2-year event-free survival (EFS) rate.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted